Iron Overload Syndrome Market Report 2025-2035, Profiles Of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

(MENAFN- GlobeNewsWire - Nasdaq) Iron overload syndrome, including hereditary hemochromatosis, is a disorder marked by excessive iron buildup in the body, primarily due to HFE gene mutations or secondary causes like chronic transfusions. Early diagnosis using serum ferritin and genetic testing is crucial to prevent irreversible damage to organs like the liver and heart. Treatments such as therapeutic phlebotomy, iron chelation, and lifestyle changes effectively manage iron levels. The global market is growing due to improved diagnostics, innovative therapies like deferasirox, and expanding genetic screening. Despite challenges, advancements in gene-based therapies and collaborative healthcare efforts are promising improved outcomes.

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "Iron Overload Syndrome Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
The global iron overload syndrome market is steadily expanding, driven by advancements in diagnostic imaging, therapeutic phlebotomy protocols, and the availability of oral iron chelation therapies. Innovations such as deferasirox and deferiprone have improved patient adherence and quality of life, particularly for those with transfusion-dependent secondary iron overload. The increasing use of non-invasive MRI-based iron quantification and expanded genetic screening programs is enabling earlier detection, thereby reducing the risk of irreversible organ damage and increasing demand for treatment.

Additionally, ongoing research into next-generation chelators, gene-based interventions for hereditary forms, and combination therapies targeting both iron excess and oxidative tissue injury promises more effective and durable outcomes. However, barriers such as the high cost of lifelong chelation therapy in resource-limited settings, delayed diagnosis due to non-specific early symptoms, and limited access to specialized care remain significant. Continued investment, public health initiatives, and collaborative efforts among industry, healthcare providers, and advocacy groups are expected to enhance access, improve treatment outcomes, and support the development of curative approaches in the future.
Key players in the iron overload syndrome market include pharmaceutical companies such as Novartis, Chiesi Group, and Regeneron Pharmaceuticals Inc., along with specialized biotech firms focused on iron metabolism disorders. These companies are investing in research to develop next-generation chelators with improved safety profiles, novel gene-based interventions for hereditary forms, and combination strategies that target both iron levels and downstream oxidative damage. Collaborative efforts between industry, research institutions, and patient advocacy organizations are enhancing awareness, expanding screening programs, and accelerating clinical trials for emerging treatments.
The competitive landscape is becoming increasingly diversified, with innovation in imaging technologies, biomarker development, and personalized therapy strategies. As gene editing and targeted molecular therapies mature, the treatment paradigm for iron overload syndrome may shift from life-long management toward potential cures in certain genetic cases. With ongoing scientific advances and expanding healthcare infrastructure, the market outlook remains positive, offering hope for improved prevention, earlier detection, and more effective treatment of this potentially life-threatening condition.
The global iron overload syndrome market is growing steadily, driven by increasing awareness, improvements in diagnostic technologies, and the rising prevalence of transfusion-dependent anemias. Advances in non-invasive MRI-based iron quantification have improved screening capabilities, enabling earlier intervention. The approval and wider adoption of oral chelating agents have enhanced patient compliance and quality of life, especially for individuals requiring long-term therapy. The market has also been bolstered by greater public health emphasis on genetic screening in high-prevalence regions, such as Northern Europe, where hereditary hemochromatosis is more common.

Key Topics Covered:
1. Global Iron Overload Syndrome Market: Industry Analysis
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Market Drivers
1.6.2 Market Restraints
1.6.3 Market Opportunities
2. Global Iron Overload Syndrome Market (by Region), ($Million), 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Iron Overload Syndrome Market, by Country ($Million), 2024-2035
2.1.2.1.1 U.S.
2.1.2.1.2 Canada
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Iron Overload Syndrome Market, by Country ($Million), 2024-2035
2.2.2.1.1 U.K.
2.2.2.1.2 France
2.2.2.1.3 Germany
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.2.2.1.6 Rest-of-Europe
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Iron Overload Syndrome Market, by Country ($Million), 2024-2035
2.3.2.1.1 Japan
2.3.2.1.2 China
2.3.2.1.3 India
2.3.2.1.4 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Iron Overload Syndrome Market: Competitive Landscape and Company Profiles
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Chiesi Group
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Novartis
3.2.3 PHARMACOSMOS A/S
3.2.4 Protagonist Therapeutics Inc
3.2.5 Regeneron Pharmaceuticals Inc.
4. Research Methodology
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01102025004107003653ID1110135070